Alles Mark J 4
4 · Syros Pharmaceuticals, Inc. · Filed Sep 19, 2023
Insider Transaction Report
Form 4
Alles Mark J
Director
Transactions
- Exercise/Conversion
Common Stock
2023-09-16+2,666→ 3,666 total - Exercise/Conversion
Restricted Stock Units
2023-09-16−2,666→ 5,334 total→ Common Stock (2,666 underlying)
Footnotes (4)
- [F1]Represents shares of common stock received upon vesting of a restricted stock unit award.
- [F2]On September 16, 2022, the issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
- [F3]Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock.
- [F4]Represents a restricted stock unit award granted on September 16, 2022. These restricted stock units vest in three equal annual installments commencing on September 16, 2023.